“We have a sense of urgency but patient safety is our utmost priority”
Melaina
Associate Director
Clinical Trial Management – Early Development
Geneva, Switzerland
Associate Director
Clinical Trial Management – Early Development
Geneva, Switzerland
I am currently involved in two studies to evaluate an early-stage drug candidate that is a MEK inhibitor, which is thought to influence a biological pathway regulating growth in normal and cancerous cells. Both studies are in patients with solid tumors.
In all our clinical trials, the safety of the patient always has utmost priority. And when you are dealing with oncology patients, you also make special efforts for their comfort.
Whether we are managing a trial internally or working with an external clinical research organization, the principles are the same. We have to ensure that the protocol is scientifically sound and designed with the right objectives, as well as being operationally feasible. Then we work with clinical investigators to make sure that everything is implemented correctly and we meet our timelines and quality.
We are constantly looking for ways to work more efficiently and streamline our processes while meeting the strict requirements of regulatory authorities. The more efficiently we do our job in Clinical Development, without compromising quality, the faster we can deliver promising new therapies to the patients who need them.
